Do Nicotine Pouches Help You Quit Smoking?

Nobody knows. On 24 October 2025 Cochrane published the first systematic review of the question and found four trials, 284 participants in total, and evidence rated very low to low certainty. The one trial that compared pouches with e-cigarettes pointed the other way. Set against 29,044 participants behind e-cigarettes and 64,640 behind nicotine replacement therapy, pouches are the least-evidenced switch on the shelf.

What the October 2025 Cochrane review found

The review is Oral nicotine pouches for cessation or reduction of use of other tobacco or nicotine products, by Jamie Hartmann-Boyce, Harry Tattan-Birch, Jamie Brown and colleagues, published on 24 October 2025 and funded by the US National Cancer Institute and the FDA Center for Tobacco Products.

The search ran from 2000 to 13 January 2025 across CENTRAL, MEDLINE, Embase and PsycINFO. What it turned up:

• Four studies, each with fewer than 150 participants, 284 in total
• Three conducted in the USA, one in New Zealand
• Three at high risk of bias, one at unclear risk
• One of the four industry-funded

Every included trial was in people who smoked cigarettes at the start. The plain-language summary puts the conclusion in one line: “We are uncertain if oral nicotine pouches help people quit smoking compared to instructions to continue smoking as usual or no support to quit.”

A second team reached the same verdict independently the same year. The systematic review Nicotine pouches and clinical outcomes related to smoking cessation, by Javad Heshmati and colleagues in Addiction, pooled seven randomised trials with 269 participants and found that the evidence does not support using nicotine pouches for smoking cessation, adding the concern that their use may sustain or increase nicotine dependence rather than end it.

One confidence interval tells the whole story

The comparison of pouches against no intervention rests on a single trial with 27 participants.

Its result: risk ratio 1.58, 95% confidence interval 0.07 to 35.32.

That interval is worth reading slowly. It says the data are compatible with pouches making someone roughly fourteen times less likely to quit, and equally compatible with making them thirty-five times more likely. A range spanning a factor of 500 is not a weak finding. It is the absence of a finding, written out in numbers.

Cochrane rated it very low-certainty evidence for exactly this reason: risk of bias plus imprecision, with the interval including the possibility of no difference at all.

Anyone quoting “studies show pouches help smokers quit” is quoting that interval’s midpoint and dropping the rest of it.

How the evidence compares with the alternatives

This is the comparison that makes the picture legible, and it is rarely drawn.

Sources for the rows: the 2025 pouch review above; Lindson and colleagues on electronic cigarettes, updated 26 August 2026, covering 90 studies; Hartmann-Boyce and colleagues on nicotine replacement therapy, 2018; and Livingstone-Banks and colleagues on smokeless tobacco cessation, 15 April 2025.

Two rows have tens of thousands of participants and high-certainty evidence. Two have 27 and 36.

The one head-to-head trial went the other way

One study, with 36 participants, randomised smokers to nicotine pouches or to e-cigarettes.

Risk ratio 0.25, 95% CI 0.03 to 2.02, low-certainty evidence. Fewer people quit on pouches. The confidence interval crosses 1, so this does not establish that pouches are worse, and Cochrane says so directly.

But it is the only direct comparison that exists, and it does not favour pouches. The review’s closing recommendation is that future trials should prioritise comparing pouches against active alternatives like nicotine replacement therapy and e-cigarettes, which is a polite way of saying the question has not been asked properly yet.

What the FDA authorisation actually says

This is the single most misread fact in the category.

On 16 January 2025 the FDA authorised the marketing of 20 Zyn products in the United States. The announcement is explicit about what that is not:

“While today’s actions permit these specific tobacco products to be legally marketed in the U.S. to adults 21 and older, it does not mean these tobacco products are safe, nor are they ‘FDA approved’.”

Matthew Farrelly, director of the FDA’s Office of Science, framed the finding as the data showing “these nicotine pouch products meet that bar by benefiting adults who use cigarettes and/or smokeless tobacco products”. That is a population-level judgement about a market, made on toxicant exposure and use patterns. It is not a clinical finding that pouches help an individual stop smoking, and the FDA did not authorise any cessation claim.

Legal to sell is not the same as proven to work.

Switching can raise your nicotine peak, not lower it

If the point of switching is less nicotine, the strength on the can decides whether that happens.

In a crossover trial at LMU Munich published in Frontiers in Pharmacology on 22 May 2024, Nadja Mallock-Ohnesorg, Andrea Rabenstein and colleagues measured peak blood nicotine in 15 smokers:

• 6 mg pouch: 2.8 ng/mL
• 20 mg pouch: 7.1 ng/mL
• 30 mg pouch: 29.4 ng/mL
• Cigarette: 15.2 ng/mL

The 30 mg pouch also raised heart rate by around 25 beats per minute, matching the cigarette, and caused strong mouth irritation. The authors concluded that pouches at 30 mg “may induce addiction” and questioned whether such doses are needed.

So a low-strength pouch is a genuine step down in peak dose. A high-strength one is a step up. Which of the two someone ends up on is usually decided by the shop shelf rather than by a plan. How the number on the can translates into the dose you receive is covered in how strong a nicotine pouch really is.

What did improve in the one trial that measured it

The case for switching is not empty, and it deserves the same accuracy as the case against.

In a trial with 53 participants, people switched to pouches showed:

• Carboxyhaemoglobin lower by 6.7 percentage points (95% CI −8.33 to −5.07), a direct marker of carbon monoxide from smoke
• NNAL, a marker of a tobacco-specific nitrosamine, lower by 265.30 ng/g creatinine (95% CI −350.64 to −179.96)

Cochrane rated both very low certainty. No serious adverse events occurred in the three studies that reported them.

Combustion is the main driver of smoking-related harm, so lower exposure when someone stops inhaling smoke is expected rather than surprising. What no trial has done is follow anyone long enough to see whether that translates into fewer diseases, and none has measured what happens to people who end up using both.

Where this leaves the decision

If you smoke and want to stop, the evidence points at nicotine replacement, e-cigarettes and counselling, in that order of how well-studied they are. Pouches are not in that group yet, and they may never be.

If you already switched and the cigarettes are gone, that is not nothing. The realistic next problem is the one the trials never followed: pouches get used across a whole day rather than in discrete breaks, so the daily dose climbs quietly and the count is the only thing that shows it.

Breezer logs each pouch with one tap and turns that into a daily and weekly total, a limit you set yourself, and the cost. Start on the snus tracker, or the Zyn tracker if that is your brand. When the number is higher than you expected, the 21-day step-down plan is the structured way to bring it down, and Quit Mode takes over from a fixed quit date with the withdrawal timeline.

For the oral-health side of the same decision, what nicotine pouches do to your gums goes through what the research has and has not established.

Sources: Heshmati J, Shahen S, Bates EL, Visintini S, Quirouette E, Mullen KA, Mir H. Nicotine pouches and clinical outcomes related to smoking cessation: A systematic review of randomized trials. Addiction, 2025. — Hartmann-Boyce J, Tattan-Birch H, Brown J, Shahab L, Goniewicz ML, Ma CL, Wu AD, Travis N, Jarman H, Livingstone-Banks J, Lindson N. Oral nicotine pouches for cessation or reduction of use of other tobacco or nicotine products. Cochrane Database of Systematic Reviews, 2025, Issue 10, CD016220.pub2. — Lindson N, Livingstone-Banks J, Butler AR et al. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews, updated 26 August 2026, CD010216. — Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews, 2018, CD000146. — Livingstone-Banks J, Vidyasagaran AL, Croucher R et al. Interventions for smokeless tobacco use cessation. Cochrane Database of Systematic Reviews, 2025, CD015314.pub2. — Mallock-Ohnesorg N, Rabenstein A, Stoll Y et al. Small pouches, but high nicotine doses. Frontiers in Pharmacology, 22 May 2024. — U.S. Food and Drug Administration, FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products After Extensive Scientific Review, 16 January 2025.

This article is not medical advice. Anyone planning to stop smoking is better served by a cessation service than by any product page, including this one.